MiNK Therapeutics (NASDAQ:INKT) Now Covered by HC Wainwright

Analysts at HC Wainwright assumed coverage on shares of MiNK Therapeutics (NASDAQ:INKT) in a report released on Wednesday. The firm set a “buy” rating and a $38.00 price target on the stock. HC Wainwright‘s price objective points to a potential upside of 252.18% from the company’s current price.

Several other analysts have also recently commented on the stock. Zacks Research cut shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Finally, B. Riley Financial reiterated a “buy” rating and set a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MiNK Therapeutics has a consensus rating of “Hold” and an average target price of $44.00.

MiNK Therapeutics Price Performance

MiNK Therapeutics stock opened at $10.79 on Wednesday. MiNK Therapeutics has a 12 month low of $8.48 and a 12 month high of $16.93. The business has a 50 day simple moving average of $11.31 and a 200-day simple moving average of $11.29. The stock has a market capitalization of $55.03 million, a PE ratio of -4.50 and a beta of 0.49.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). As a group, equities research analysts anticipate that MiNK Therapeutics will post -2.20 EPS for the current year.

Insider Activity at MiNK Therapeutics

In related news, CEO Jennifer Buell sold 6,938 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer owned 74,195 shares in the company, valued at $783,499.20. This trade represents a 8.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by company insiders.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.